Prevention of Bone Loss with Risedronate in Breast Cancer Survivors: A Randomized, Controlled Clinical Trial

PURPOSE: Aromatase inhibitors (AIs), adjuvant endocrine therapy for postmenopausal women with hormone receptor positive breast cancer, are associated with bone loss and fractures. Our objectives were to determine if 1) oral bisphosphonate therapy can prevent bone loss in women on an AI and, 2) early...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Osteoporos Int
Main Authors: Greenspan, Susan L., Vujevich, Karen T., Brufsky, Adam, Lembersky, Barry C., van Londen, G.J., Jankowitz, Rachel C., Puhalla, Shannon L., Rastogi, Priya, Perera, Subashan
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4766869/
https://ncbi.nlm.nih.gov/pubmed/25792492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00198-015-3100-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados